Lupin launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in USA
The product is approved as bioequivalent to Xigduo XR for the indications outlined in the reference drug’s labelling
The product is approved as bioequivalent to Xigduo XR for the indications outlined in the reference drug’s labelling
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
This product will be manufactured at Lupin’s Pithampur facility in India
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus
This product will be manufactured at Lupin’s Pithampur facility in India
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Subscribe To Our Newsletter & Stay Updated